Multiple Myeloma Clinical Trials in Durham, North Carolina

10 studies are recruiting for multiple myeloma in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Durham VAMC, Durham, North Carolina

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

2. A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

   The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste ch…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   38 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06500884 on ClinicalTrials.gov

3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Durham VAMC, Durham, North Carolina

   Locations

   144 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

4. A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

   A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University Hospital, Durham, North Carolina

   Locations

   26 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT05651932 on ClinicalTrials.gov

5. Selinexor and Backbone Treatments of Multiple Myeloma Patients

   This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Institute of Cancer/ Duke University, Durham, North Carolina

   Locations

   25 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT02343042 on ClinicalTrials.gov

6. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

   This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   212 in total

   Run by

   European Myeloma Network B.V.

   See if you can join NCT05243797 on ClinicalTrials.gov

7. Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

   This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke Comprehensive Cancer Center, Durham, North Carolina

   Locations

   5 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT05145400 on ClinicalTrials.gov

8. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

   This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University Health System (DUHS), Durham, North Carolina

   Locations

   32 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT05828511 on ClinicalTrials.gov

9. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

   A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   104 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04988555 on ClinicalTrials.gov

10. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

    The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke, Durham, North Carolina

    Locations

    7 in total

    Run by

    Carevive Systems, Inc.

    See if you can join NCT05974150 on ClinicalTrials.gov